Reshape Lifesciences Stock EBITDA

RSLS Stock

USD 0.62 0.01 1.59%

ReShape Lifesciences fundamentals help investors to digest information that contributes to ReShape Lifesciences' financial success or failures. It also enables traders to predict the movement of ReShape Stock. The fundamental analysis module provides a way to measure ReShape Lifesciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ReShape Lifesciences stock.

		Last Reported	Projected for Next Year
	EBITDA	-13 M	-13.7 M

EBITDA is likely to drop to about (13.7 M) in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

ReShape Lifesciences Company EBITDA Analysis

ReShape Lifesciences' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current ReShape Lifesciences EBITDA

(14.48 M)

Most of ReShape Lifesciences' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ReShape Lifesciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

ReShape EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for ReShape Lifesciences is extremely important. It helps to project a fair market value of ReShape Stock properly, considering its historical fundamentals such as EBITDA. Since ReShape Lifesciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ReShape Lifesciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ReShape Lifesciences' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Retained Earnings	Total Liab	Net Debt	Accounts Payable	Long Term Debt	Net Receivables	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Short Term Investments	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.97	-0.1	0.58	-0.31	0.32	-0.21	0.22	0.29	0.25	0.14	0.03	0.38	0.28	-0.07	-0.04	0.23	0.28	0.13	0.11	0.05
Total Stockholder Equity	0.97		-0.1	0.38	-0.32	0.25	-0.22	0.17	0.28	0.21	0.11	0.11	0.47	0.27	0.04	-0.01	0.22	0.28	0.15	0.25	0.07
Retained Earnings	-0.1	-0.1		-0.04	-0.23	-0.7	-0.54	-0.76	0.24	0.31	0.52	-0.32	0.32	-0.59	0.41	-0.75	-0.92	-0.43	0.88	0.03	0.85
Total Liab	0.58	0.38	-0.04		-0.09	0.38	-0.09	0.29	0.15	0.29	0.19	-0.26	-0.16	0.2	-0.46	-0.1	0.12	0.11	-0.02	-0.45	-0.07
Net Debt	-0.31	-0.32	-0.23	-0.09		0.21	0.09	0.2	-0.95	0.04	-0.5	-0.55	0.15	0.14	-0.71	0.14	0.33	0.12	-0.45	-0.68	-0.22
Accounts Payable	0.32	0.25	-0.7	0.38	0.21		0.39	0.96	-0.19	-0.31	-0.57	0.17	-0.19	0.5	-0.37	0.47	0.8	0.53	-0.64	-0.1	-0.8
Long Term Debt	-0.21	-0.22	-0.54	-0.09	0.09	0.39		0.47	0.06	-0.35	-0.51	0.62	-0.23	0.19	0.08	0.83	0.51	0.34	-0.71	0.08	-0.69
Net Receivables	0.22	0.17	-0.76	0.29	0.2	0.96	0.47		-0.17	-0.39	-0.56	0.22	-0.21	0.44	-0.33	0.49	0.84	0.48	-0.73	-0.11	-0.89
Total Current Assets	0.29	0.28	0.24	0.15	-0.95	-0.19	0.06	-0.17		0.04	0.47	0.52	-0.22	-0.17	0.7	-0.07	-0.35	-0.11	0.36	0.59	0.18
Short Term Debt	0.25	0.21	0.31	0.29	0.04	-0.31	-0.35	-0.39	0.04		0.37	-0.41	-0.11	-0.16	-0.14	-0.41	-0.27	0.0	0.29	-0.19	0.59
Common Stock	0.14	0.11	0.52	0.19	-0.5	-0.57	-0.51	-0.56	0.47	0.37		-0.1	-0.15	-0.56	0.2	-0.57	-0.59	-0.17	0.61	0.09	0.59
Property Plant Equipment	0.03	0.11	-0.32	-0.26	-0.55	0.17	0.62	0.22	0.52	-0.41	-0.1		-0.1	0.03	0.61	0.52	0.27	0.19	-0.18	0.75	-0.37
Short Term Investments	0.38	0.47	0.32	-0.16	0.15	-0.19	-0.23	-0.21	-0.22	-0.11	-0.15	-0.1		-0.06	0.1	-0.19	-0.12	-0.13	0.32	0.05	0.29
Current Deferred Revenue	0.28	0.27	-0.59	0.2	0.14	0.5	0.19	0.44	-0.17	-0.16	-0.56	0.03	-0.06		-0.26	0.56	0.53	0.22	-0.45	-0.06	-0.42
Net Tangible Assets	-0.07	0.04	0.41	-0.46	-0.71	-0.37	0.08	-0.33	0.7	-0.14	0.2	0.61	0.1	-0.26		-0.1	-0.45	-0.15	0.47	0.8	0.29
Long Term Debt Total	-0.04	-0.01	-0.75	-0.1	0.14	0.47	0.83	0.49	-0.07	-0.41	-0.57	0.52	-0.19	0.56	-0.1		0.68	0.48	-0.78	0.1	-0.72
Capital Surpluse	0.23	0.22	-0.92	0.12	0.33	0.8	0.51	0.84	-0.35	-0.27	-0.59	0.27	-0.12	0.53	-0.45	0.68		0.57	-0.84	-0.08	-0.83
Short Long Term Debt	0.28	0.28	-0.43	0.11	0.12	0.53	0.34	0.48	-0.11	0.0	-0.17	0.19	-0.13	0.22	-0.15	0.48	0.57		-0.44	-0.06	-0.41
Net Invested Capital	0.13	0.15	0.88	-0.02	-0.45	-0.64	-0.71	-0.73	0.36	0.29	0.61	-0.18	0.32	-0.45	0.47	-0.78	-0.84	-0.44		0.3	0.88
Net Working Capital	0.11	0.25	0.03	-0.45	-0.68	-0.1	0.08	-0.11	0.59	-0.19	0.09	0.75	0.05	-0.06	0.8	0.1	-0.08	-0.06	0.3		0.1
Capital Stock	0.05	0.07	0.85	-0.07	-0.22	-0.8	-0.69	-0.89	0.18	0.59	0.59	-0.37	0.29	-0.42	0.29	-0.72	-0.83	-0.41	0.88	0.1

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict ReShape Lifesciences

Ebitda Over Time

ReShape Ebitda

Ebitda

(13.69 Million)

At this time, ReShape Lifesciences' EBITDA is comparatively stable compared to the past year.

According to the company disclosure, ReShape Lifesciences reported earnings before interest,tax, depreciation and amortization of (14.48 Million). This is 101.65% lower than that of the Health Care Equipment & Supplies sector and 102.25% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.37% higher than that of the company.

ReShape EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ReShape Lifesciences' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ReShape Lifesciences could also be used in its relative valuation, which is a method of valuing ReShape Lifesciences by comparing valuation metrics of similar companies.

ReShape Lifesciences is currently under evaluation in ebitda category among its peers.

ReShape Lifesciences Current Valuation Drivers

We derive many important indicators used in calculating different scores of ReShape Lifesciences from analyzing ReShape Lifesciences' financial statements. These drivers represent accounts that assess ReShape Lifesciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ReShape Lifesciences' important valuation drivers and their relationship over time.

	2020	2021	2022	2023	2024	2025 (projected)
Market Cap	17.6M	17.9M	2.9M	1.5M	1.7M	1.6M
Enterprise Value	15.1M	(4.6M)	(823.6K)	(2.7M)	(3.1M)	(3.0M)

ReShape Lifesciences Institutional Holders

Institutional Holdings refers to the ownership stake in ReShape Lifesciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ReShape Lifesciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ReShape Lifesciences' value.

		Shares
Geode Capital Management, Llc	2024-09-30	0.0
Jpmorgan Chase & Co	2024-12-31	0.0
Virtu Financial Llc	2024-09-30	0.0
Xtx Topco Ltd	2024-09-30	0.0
Hrt Financial Llc	2024-09-30	0.0
Ubs Group Ag	2024-12-31	17.7 K
Tower Research Capital Llc	2024-12-31	847
Blackrock Inc	2024-12-31	588
Bank Of America Corp	2024-12-31	6.0
Group One Trading, Lp	2024-12-31	2.0
Atlantic Trust Group, Llc	2024-12-31	1.0

ReShape Fundamentals

	Return On Equity	-1.85
	Return On Asset	-0.63
	Profit Margin	(1.12) %
	Operating Margin	(1.05) %
	Current Valuation	1.54 M
	Shares Outstanding	712.68 K
	Shares Owned By Insiders	5.57 %
	Shares Owned By Institutions	1.83 %
	Number Of Shares Shorted	82.81 K
	Price To Book	1.41 X
	Price To Sales	0.26 X
	Revenue	8.68 M
	Gross Profit	6.8 M
	EBITDA	(14.48 M)
	Net Income	(11.39 M)
	Cash And Equivalents	11.49 M
	Cash Per Share	0.51 X
	Total Debt	262 K
	Debt To Equity	0.01 %
	Current Ratio	2.12 X
	Book Value Per Share	16.48 X
	Cash Flow From Operations	(16.96 M)
	Short Ratio	0.22 X
	Earnings Per Share	76.20 X
	Price To Earnings To Growth	(12.12) X
	Target Price	1.0
	Number Of Employees	29
	Beta	1.35
	Market Capitalization	3.64 M
	Total Asset	10.66 M
	Retained Earnings	(635.57 M)
	Working Capital	6.52 M
	Net Asset	10.66 M

About ReShape Lifesciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze ReShape Lifesciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ReShape Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ReShape Lifesciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for ReShape Stock Analysis

When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC